NRAS and melanoma: In this manuscript, we describe a potential new therapy for patients with this subtype by characterizing the mechanism by which NRAS-mutant melanoma cells resist the effects of MEKi via short-term adaptive/intrinsic resistance and long-term acquired resistance.